Application of Modeling in Therapeutic R&D

Applied BioMath provides a full range of services from target feasibility to late stage clinical study support. Our team will help you determine what services best meet the needs of your project based on the data you have, the scientific questions you are trying to answer, your biology, and your timelines. Each project is unique and we invite you to contact us to discuss your project. 

Modeling Applications by Modality

Our modeling approach is applicable to various modalities, including but not limited to the following. 

Protein Therapies
Small Molecules
  • Irreversible Binders
  • Prodrugs
  • Protein Degraders
  • Kinase Inhibitor
Cell & Gene Therapies

 

Modeling Applications by Indication

Our experience spans many indications, including but not limited to the following. 

Oncology
Cardiovascular Disease 
Chronic Kidney Disease
Immuno-oncology
CNS/Alzheimer's Disease
Pain
Inflammation & Immunology
Infectious Disease
Rare & Orphan Diseases
Metabolic Disease
Ophthalmology
Respiratory Disease

 

Modeling Applications by Pipeline Stage

Our services span the entire R&D pipeline. We help groups answer many different types of questions depending on the specific project and the project stage. Following is a sample of the types of questions we help answer often.

R&D pipeline

Questions Typically Asked Early in R&D
  • Which step of the signaling cascade do we target?
  • What affinity do we need (e.g. 1 pM vs. 1 nM)?
  • Selectivity (e.g. 10x, 100x, 1000x) for desired target to improve therapeutic index?
  • How do I prioritize my experiments?
  • How do I optimize my experimental design in the context of study limitations?
  • What are optimal drug properties?
  • Which of our preclinical candidates should we move forward?
Questions Typically Asked Later in R&D
  • How does my program compare against the standard of care or future standards of care?
  • How do I select the starting dose for my first-in-human study?
  • What is the predicted efficacious dose for my molecule?
  • What is R2PD dose based on phase 1 data?
  • How do we optimize the therapeutic window?
  • What patients? Indications?
  • Why didn't my trial work?
  • Will someone come along and take this target space?
  • How do we differentiate our candidate from competitors?

What Scientific Questions Are You Trying to Answer?

We'll put you in touch with the right person on our team. 

Contact Us